Bausch + Lomb Corporation


SKU: BLCO Category:


This is our first report on eye health major, Bausch + Lomb Corporation. The company’s Q3 2023 Earnings Call reported an 8% increase in revenue, growth attributed to strengths across its well[1]established and emerging brands that cover the whole spectrum of eye health. The firm appears poised to maintain this growth trend into 2024, which it anticipates will be one of the most active launch years in its 170-year history. New product launches are planned across the company’s entire portfolio, including high-margin, fast-growing areas of the market.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!